Abzena, UCL deal
Abzena's Antitope Ltd. subsidiary and University College London partnered to humanize an anti- leucine-rich alpha-2-glycoprotein 1 (LRG1) antibody as part of a Medical Research Council (MRC)-funded translational research and product development program at the UCL Institute of Ophthalmology. UCL's UCL Business plc technology transfer company, which holds the patents to UCL's LRG1 technologies, provided an undisclosed amount in initial proof-of-concept funding. Antitope will produce a range of fully humanized antibodies using its Composite Human Antibody technology that are designed to bind to and inhibit LRG1. UCL will select a lead antibody for further development to treat age-related macular degeneration (AMD) and plans to out-license the antibody for commercialization. ...